Editas Medicine To Deliver EDIT-401 Oral Presentation At European Society Of Gene And Cell Therapy Congress, October 7–10, 2025, In Seville, Spain
Benzinga Newsdesk 1 year ago
BiotechNewsGeneral
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.
- European Society of Gene and Cell Therapy (ESGCT) Congress
Title: A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates
Session Date and Time: Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET
Session Title: 9A: Gene Editing II, Ex Vivo Applications
Room: Parallel A
Presenter: Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer, Editas Medicine
Final Abstract Number: OR069
Abstracts are available to registrants on the ESGCT website. The oral presentation will also be posted to the "Posters & Presentations" section of the Company's website at the time of the presentation and will remain accessible following the event.